It's never too early to get the speculation starte
Post# of 36537
(Total Views: 357)
Posted On: 01/01/2019 10:31:20 AM
It's never too early to get the speculation started for the new year. I know this (below) was posted earlier, but I didn't realize it was from the Motley Fool. I'm not sure if they are blowing smoke, or actually believe this.
I have followed and been invested in GW Phar. (GWPH) for more than a year. IMO, GWPH is the best all around medical cannabis investment. It is an English company that is well-financed. It's childhood epilepsy drug, Epediolex, has been approved by the FDA. My understanding is that Epediolex is derived from one cannabis molecule. GWPH's research will focus on other molecules to address other conditions. When MF states that Kali and GNBT present competition to GWPH, that's heady stuff. I hope it's true
"New York, NY -- December 24, 2018 -- InvestorsHub NewsWire -- via nextbigticker.com -- Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) and Generex Biotechnology Corp (OTCQB: GNBT) through a deal announced between GNBT and US Cannabis Health, a Joint Venture partnership between KALY and Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals (USOTC: NOUV) could potentially soon introduce a cannabis drug that not only rivals GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, KALY and GNBT’s cannabis drug development could reveal that GWPH’s Epidiolex infringes on GNBT patents.
"I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognized by the market," said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals [GW Pharmaceuticals, plc (GWPH)]. As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be realized value. Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets." (source - yahoo.com)
I have followed and been invested in GW Phar. (GWPH) for more than a year. IMO, GWPH is the best all around medical cannabis investment. It is an English company that is well-financed. It's childhood epilepsy drug, Epediolex, has been approved by the FDA. My understanding is that Epediolex is derived from one cannabis molecule. GWPH's research will focus on other molecules to address other conditions. When MF states that Kali and GNBT present competition to GWPH, that's heady stuff. I hope it's true
"New York, NY -- December 24, 2018 -- InvestorsHub NewsWire -- via nextbigticker.com -- Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) and Generex Biotechnology Corp (OTCQB: GNBT) through a deal announced between GNBT and US Cannabis Health, a Joint Venture partnership between KALY and Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals (USOTC: NOUV) could potentially soon introduce a cannabis drug that not only rivals GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, KALY and GNBT’s cannabis drug development could reveal that GWPH’s Epidiolex infringes on GNBT patents.
"I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognized by the market," said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals [GW Pharmaceuticals, plc (GWPH)]. As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be realized value. Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets." (source - yahoo.com)
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼